ST Phi Therapeutics

Clinical-stage next-generation universal cell therapy company targeting oncology and autoimmune diseases. It has an off-the-shelf T-cell therapy platform featuring NK cell characteristics. Lead product has demonstrated promising safety and efficacy in GvHD and T cells mediated autoimmune diseases patients in an IIT study